Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid Endarterectomy

Neurosurgery

Volumn 74, Issue 3, 2014, Pages 254-260

  Vellimana, Ananth K ^a   Yarbrough, Chester K ^a   Blackburn, Spiros ^c   Strom, Russell G ^a   Pilgram, Thomas K ^b   Lee, Jin Moo ^a   Grubb, Robert L ^a   Rich, Keith M ^a   Chicoine, Michael R ^a   Dacey, Ralph G ^a   Derdeyn, Colin P ^a,b   Zipfel, Gregory J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Carotid endarterectomy; Intracerebral hemorrhage; Thrombolysis; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADMINISTRATION, INTRAVENOUS; AGED; BLOOD PRESSURE; CAROTID STENOSIS; CEREBRAL HEMORRHAGE; ENDARTERECTOMY, CAROTID; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84896732512     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000261     Document Type: Article

References (23)

1. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):2945-2948.
2. Govan L,Weir CJ, Langhorne P. Organized inpatient (stroke unit) care for stroke. Stroke. 2008;39(8):2402-2403.
3. Derdeyn CP, Panagos PD. Stroke center certification: where are we in 2010? J Neurointerv Surg. 2010;2(1):41-43.
4. Dirks M, Niessen LW, van Wijngaarden JD, et al. Promoting thrombolysis in acute ischemic stroke. Stroke. 2011;42(5):1325-1330.
5. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Neurointerventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Stroke. 2011;81(1): E76-E123.
6. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363(9413):915-924.
7. Bartoli MA, Squarcioni C, Nicoli F, et al. Early carotid endarterectomy after intravenous thrombolysis for acute ischaemic stroke. Eur J Vasc Endovasc Surg. 2009;37(5):512-518.
8. Crozier JE, Reid J, Welch GH, Muir KW, Stuart WP. Early carotid endarterectomy following thrombolysis in the hyperacute treatment of stroke. Br J Surg. 2011;98(2):235-238.
9. McPherson CM, Woo D, Cohen PL, et al. Early carotid endarterectomy for critical carotid artery stenosis after thrombolysis therapy in acute ischemic stroke in the middle cerebral artery. Stroke. 2001;32(9):2075-2080.
10. Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIH Stroke Scale score from medical records. Stroke. 1999;30(8):1534-1537.
11. North American Symptomatic Carotid Endarterectomy Trial: methods, patient characteristics, and progress. Stroke. 1991;22(6):711-720.
12. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413.
13. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857-872.
14. Leseche G, Alsac JM, Houbbalah R, et al. Carotid endarterectomy in the acute phase of stroke-in-evolution is safe and effective in selected patients. J Vasc Surg. 2012;55(3):701-707.
15. Rathenborg LK, Jensen LP, Baekgaard N, Schroeder TV. Carotid endarterectomy after intravenous thrombolysis for acute cerebral ischaemic attack: is it safe? Eur J Vasc Endovasc Surg. 2013;45(6):573-577.
16. Yong YP, Saunders J, Abisi S, et al. Safety of carotid endarterectomy following thrombolysis for acute ischemic stroke. J Vasc Surg. 2013;58(6):1671-1677.
17. Piepgras DG,MorganMK, Sundt TMJr, Yanagihara T, Mussman LM. Intracerebral hemorrhage after carotid endarterectomy. J Neurosurg. 1988;68(4):532-536.
18. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96(3):761-768.
19. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke: the NINDS t-PA Stroke Study Group. Stroke. 1997;28(11):2109-2118.
20. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.
21. Tsuji K, Aoki T, Tejima E, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005;36(9): 1954-1959.
22. Ning M, Furie KL, Koroshetz WJ, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006;66(10): 1550-1555.
23. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107(4):598-603.